Reactive oxygen species and autophagy associated apoptosis and limitation of clonogenic survival induced by zoledronic acid in salivary adenoid cystic carcinoma cell line SACC-83

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Ge, Xi Yuan ^a   Yang, Lin Qian ^a   Jiang, Yang ^a   Yang, Wen Wen ^a   Fu, Jia ^a   Li, Sheng N ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PROTEIN BCL 2; PROTEIN BCL XL; REACTIVE OXYGEN METABOLITE; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ADENOID CYSTIC CARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL VIABILITY; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; RNA INTERFERENCE; SALIVARY ADENOID CYSTIC CARCINOMA; SHORT TANDEM REPEAT; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, ADENOID CYSTIC; CELL CYCLE; CELL PROLIFERATION; DRUG COMBINATION; DRUG EFFECTS; DRUG SCREENING; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; NUDE MOUSE; PATHOLOGY; SALIVARY GLAND NEOPLASMS; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AUTOPHAGY; BLOTTING, WESTERN; BONE DENSITY CONSERVATION AGENTS; CARCINOMA, ADENOID CYSTIC; CELL CYCLE; CELL PROLIFERATION; CISPLATIN; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMIDAZOLES; MICE; MICE, INBRED BALB C; MICE, NUDE; PACLITAXEL; REACTIVE OXYGEN SPECIES; SALIVARY GLAND NEOPLASMS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903528331     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101207     Document Type: Article

References (52)

1. Matsuba HM, Spector GJ, Thawley SE, Simpson JR, Mauney M, et al. (1986) Adenoid cystic salivary gland carcinoma. A histopathologic review of treatment failure patterns. Cancer 57: 519-524. (Pubitemid 16164603)
2. Sung MW, Kim KH, Kim JW, Min YG, Seong WJ, et al. (2003) Clinicopathologic predictors and impact of distant metastasis from adenoid cystic carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 129: 1193-1197. (Pubitemid 37433155)
3. Hitre E, Budai B, Takacsi-Nagy Z, Rubovszky G, Toth E, et al. (2013) Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial. Br J Cancer.
4. van Weert S, Bloemena E, van der Waal I, de Bree R, Rietveld DH, et al. (2013) Adenoid cystic carcinoma of the head and neck: A single-center analysis of 105 consecutive cases over a 30-year period. Oral Oncol 49: 824-829.
5. Grimm M, Henopp T, Hoefert S, Schaefer F, Kluba S, et al. (2012) Multiple osteolytic lesions of intraosseous adenoid cystic carcinoma in the mandible mimicking apical periodontitis. Int Endod J 45: 1156-1164.
6. van der Wal JE, Becking AG, Snow GB, van der Waal I (2002) Distant metastases of adenoid cystic carcinoma of the salivary glands and the value of diagnostic examinations during follow-up. Head Neck 24: 779-783. (Pubitemid 34857305)
7. Jaso J, Malhotra R (2011) Adenoid cystic carcinoma. Arch Pathol Lab Med 135: 511-515.
8. Fordice J, Kershaw C, El-Naggar A, Goepfert H (1999) Adenoid cystic carcinoma of the head and neck: predictors of morbidity and mortality. Arch Otolaryngol Head Neck Surg 125: 149-152. (Pubitemid 29085262)
9. Heymann D, Ory B, Gouin F, Green JR, Redini F (2004) Bisphosphonates: new therapeutic agents for the treatment of bone tumors. Trends Mol Med 10: 337-343. (Pubitemid 38881523)
10. Zhao M, Tominaga Y, Ohuchida K, Mizumoto K, Cui L, et al. (2012) Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer. Cancer Sci 103: 58-66.
11. Silverman SL (2008) Paget disease of bone: therapeutic options. J Clin Rheumatol 14: 299-305.
12. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, et al. (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356: 1809-1822. (Pubitemid 46698462)
13. Coleman RE (2004) Bisphosphonates: clinical experience. Oncologist 9 Suppl 4: 14-27.
14. Polascik TJ, Mouraviev V (2008) Zoledronic acid in the management of metastatic bone disease. Ther Clin Risk Manag 4: 261-268. (Pubitemid 351460950)
15. Green JR (2003) Antitumor effects of bisphosphonates. Cancer 97: 840-847.
16. Tassone P, Tagliaferri P, Viscomi C, Palmieri C, Caraglia M, et al. (2003) Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer 88: 1971-1978. (Pubitemid 36829676)
17. Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T (2004) Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 10: 4559-4567. (Pubitemid 38878900)
18. Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, et al. (2003) Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 9: 295-306. (Pubitemid 36109746)
19. Sewing L, Steinberg F, Schmidt H, Goke R (2008) The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis. Apoptosis 13: 782-789.
20. Berenson JR (2005) Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 10: 52-62.
21. Li SL (1990) [Establishment of a human cancer cell line from adenoid cystic carcinoma of the minor salivary gland]. Zhonghua Kou Qiang Yi Xue Za Zhi 25: 29-31, 62.
22. Dong L, Ge XY, Wang YX, Yang LQ, Li SL, et al. (2013) Transforming growth factor-beta and epithelial-mesenchymal transition are associated with pulmonary metastasis in adenoid cystic carcinoma. Oral Oncol 49: 1051-1058.
23. Dong L, Wang YX, Li SL, Yu GY, Gan YH, et al. (2011) TGF-beta1 promotes migration and invasion of salivary adenoid cystic carcinoma. J Dent Res 90: 804-809.
24. Han NL, Luo F, Bian ZP, Han JS (2000) Synergistic effect of cholecystokinin octapeptide and angiotensin II in reversal of morphine induced analgesia in rats. Pain 85: 465-469. (Pubitemid 30214174)
25. Tallarida RJ (2001) Drug synergism: its detection and applications. J Pharmacol Exp Ther 298: 865-872.
26. Tallarida RJ (1992) Statistical analysis of drug combinations for synergism. Pain 49: 93-97.
27. Tallarida RJ (1992) A further comment on testing for drug synergism. Pain 51: 381-382; author reply 383-387.
28. Tallarida RJ (2011) Quantitative methods for assessing drug synergism. Genes Cancer 2: 1003-1008.
29. Sieber P, Lardelli P, Kraenzlin CA, Kraenzlin ME, Meier C (2013) Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice. Clin Drug Investig 33: 117-122.
30. Recknor C (2011) Zoledronic acid for prevention and treatment of osteoporosis. Expert Opin Pharmacother 12: 807-815.
31. Richhariya A, Qian Y, Zhao Y, Chung K (2012) Time associated with intravenous zoledronic acid administration in patients with breast or prostate cancer and bone metastasis. Cancer Manag Res 4: 55-60.
32. Liu Q, Tao YH, Bai RZ, Chang SJ, Hua D (2013) Zoledronic acid inhibits growth of hepatocellular carcinoma cells in vitro and in vivo. Chin Med J (Engl) 126: 1486-1490.
33. Ibrahim T, Mercatali L, Sacanna E, Tesei A, Carloni S, et al. (2012) Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid. Cancer Cell Int 12: 48.
34. Chang J, Wang W, Zhang H, Hu Y, Yin Z (2012) Bisphosphonates regulate cell proliferation, apoptosis and pro-osteoclastic expression in MG-63 human osteosarcoma cells. Oncol Lett 4: 299-304.
35. Zwolak P, Manivel JC, Jasinski P, Kirstein MN, Dudek AZ, et al. (2010) Cytotoxic effect of zoledronic acid-loaded bone cement on giant cell tumor, multiple myeloma, and renal cell carcinoma cell lines. J Bone Joint Surg Am 92: 162-168.
36. Lin JF, Lin YC, Lin YH, Tsai TF, Chou KY, et al. (2011) Zoledronic acid induces autophagic cell death in human prostate cancer cells. J Urol 185: 1490-1496.
37. Di Salvatore M, Orlandi A, Bagala C, Quirino M, Cassano A, et al. (2011) Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line. Cell Prolif 44: 139-146.
38. Ohnuki H, Izumi K, Terada M, Saito T, Kato H, et al. (2012) Zoledronic acid induces S-phase arrest via a DNA damage response in normal human oral keratinocytes. Arch Oral Biol 57: 906-917.
39. Romani AA, Desenzani S, Morganti MM, La Monica S, Borghetti AF, et al. (2009) Zoledronic acid determines S-phase arrest but fails to induce apoptosis in cholangiocarcinoma cells. Biochem Pharmacol 78: 133-141.
40. Li YY, Chang JW, Chou WC, Liaw CC, Wang HM, et al. (2008) Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. Lung Cancer 59: 180-191. (Pubitemid 351181343)
41. Almubarak H, Jones A, Chaisuparat R, Zhang M, Meiller TF, et al. (2011) Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers. J Carcinog 10: 2.
42. Li XY, Lin YC, Huang WL, Lin W, Wang HB, et al. (2012) Zoledronic acid inhibits human nasopharyngeal carcinoma cell proliferation by activating mitochondrial apoptotic pathway. Med Oncol.
43. Koto K, Murata H, Kimura S, Horie N, Matsui T, et al. (2010) Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents. Oncol Rep 24: 233-239.
44. Wang J, Yi J (2008) Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biol Ther 7: 1875-1884.
45. Koto K, Murata H, Kimura S, Sawai Y, Horie N, et al. (2013) Zoledronic acid significantly enhances radiationinduced apoptosis against human fibrosarcoma cells by inhibiting radioadaptive signaling. Int J Oncol 42: 525-534.
46. Bruzzese F, Pucci B, Milone MR, Ciardiello C, Franco R, et al. (2013) Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways. Cell Death Dis 4: e878.
47. Berenbaum MC (1989) What is synergy? Pharmacol Rev 41: 93-141.
48. Greco WR, Bravo G, Parsons JC (1995) The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47: 331-385.
49. Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI (2001) The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 84: 1126-1134. (Pubitemid 32448513)
50. Ibrahim T, Liverani C, Mercatali L, Sacanna E, Zanoni M, et al. (2013) Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines. Int J Oncol 42: 1263-1270.
51. Budman DR, Calabro A (2006) Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents. Oncology 70: 147-153. (Pubitemid 43760341)
52. Ozturk OH, Bozcuk H, Burgucu D, Ekinci D, Ozdogan M, et al. (2007) Cisplatin cytotoxicity is enhanced with zoledronic acid in A549 lung cancer cell line: preliminary results of an in vitro study. Cell Biol Int 31: 1069-1071. (Pubitemid 46819059)